PT -期刊文章AU -加布里埃尔Bsteh盟-丽莎Nothegger AU -克劳斯Berek AU - Felix Ladstatter盟Stefan Raschbacher AU -塞巴斯蒂安Wurth盟-迈克尔·奥尔盟哈拉尔德Hegen AU - Franziska Di泡利盟Florian Deisenhammer AU -马库斯Reindl盟Andreas Lutterotti AU -托马斯·伯杰TI -嗅觉阈值预测短期复发缓和多发性硬化复发活动(P2.347) DP - 2017年4月18日TA -神经病学PG - P2.347 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P2.347.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/P2.347.full首页所以Neurology2017 4月18日;88 AB -目的:调查协会的嗅觉阈值和疾病在一群复发缓和多发性硬化症和确定其作为疾病活动的潜在生物标志物。背景:嗅觉阈值被认为是多发性硬化炎性疾病活动的一个标志。设计/方法:在这种预期,两年的观察研究,包括103名RRMS患者。嗅觉阈值评估使用Sniffin的棍子。结果与年龄、性别、疾病,持续时间复发,扩大残疾状态量表(eds)、疾病修饰治疗(DMT),抑郁,吸烟和认知功能(以个位数模式测试,SDMT)通过多元回归模型。结果:嗅觉阈值在基线是负相关的复发在随后的12个月(r =−0.413;术;0.0001)但不是在随后的24个月(r =−0.125;p = 0.167)和年龄、疾病持续时间、抑郁、吸烟、eds或SDMT。阈值在12月发生复发之间的负相关月12和24 (r =−0.399;术中,0.0001)。基线嗅觉阈值在12或24个月,没有预测阈值阈值在12月预测阈值也在月24。有效态相比,儿童(干扰素β,glatirameracetate dimethylfumarate)患者接受高效与儿童(natalizumab fingolimod)最好嗅觉阈值在基线,12月24日。 A threshold score of 5 or lower was associated with an increased risk of relapse in the subsequent 12 months at baseline (HR 3.1; p<0.001) and at month 12 (HR 2.9; p<0.001).Conclusions: Olfactory threshold is a marker of short term inflammatory disease activity. Olfactory threshold is a useful and easily obtainable parameter to stratify patients regarding the level of inflammatory activity and possibly treatment response.Disclosure: Dr. Bsteh has nothing to disclose. Dr. Nothegger has nothing to disclose. Dr. Berek has nothing to disclose. Dr. Ladstätter has nothing to disclose. Dr. Raschbacher has nothing to disclose. Dr. Wurth has nothing to disclose. Dr. Auer has nothing to disclose. Dr. Hegen has received personal compensation for activities with Bayer Schering, Biogen Idec, Merck Serono, Novartis and TEVA Pharmaceuticals Europe. Dr. Di Pauli has nothing to disclose. Dr. Deisenhammer has received personal compensation for activities with Biogen, Sanofi Genzyme, Merck, and Novartis. Dr. Deisenhammer has received research support from Biogen. Dr. Reindl has nothing to disclose. Dr. Lutterotti has nothing to disclose. Dr. Berger has received personal compensation for activities with Biogen as a consultant and speaker. Dr. Berger's institution (Universitätsklinik für Neurologie) has received research support from Biogen.